Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

CRS Questionnaire Validation Project

NCT06970977 · tracked via the Priya Life Science Italy tracker
Sponsor
The European Forum for Research and Education in Allergy and Airway Diseases
Phase
Observational
Started
2024-09-01
Last updated
2026-09-09

Condition(s) studied

Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps

Study summary

The 'CRS validation project' consists of a joint effort of 32 medical centers in Europe, the USA, and South Africa to carry out the validation of 2 novel questionnaires designated to measure self-perceived severity and control of Chronic Rhinosinusitis (with or without nasal polyps).

This study will validate translated versions of the same set of questionnaires simultaneously in the centers involved after recruiting a total of 1000 patients, while data collection, statistical analysis, and creation of the study report will be carried out by the statistical department of the University of Leuven.

Patients will be recruited from the regular ENT practice of their hospital to minimize the complexity of the study.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient capable of giving informed consent * Diagnosis of chronic rhinosinusitis with or without nasal polyposis according to the EPOS guidelines * No recent sinus surgery (within the last three months) Exclusion Criteria: * Not capable of giving informed consent * No CRS * Recent sinus surgery (within the last three months)

Primary outcome measure(s)

  • Validation of a new questionnaire — Through study completion, an average of 6 months
    Validation of a questionnaire based on similar questionnaires already approved for use in other airway diseases. The aim to measure the current perceived status of a patient with chronic rhinosinusitis in terms of control and severity. A new questionnaire will be tested and compared with current tools. For this purpose, a set of questionnaires has been developed including the EPOS criteria for chronic rhinosinusitis, the SNOT-22, the patient global assessment tool and the VAS scores, among others. All these questionnaires will be completed by the patient at visit 1 and the results will be analysed once the recruitment target of 1,000 patients has been reached. No second patient participation is required.
  • Evaluation of the results — Through study completion, an average of 6 months
    Evaluation of the results of this questionnaire in comparison with other tools currently available. Once the target of recruiting 1000 patients has been reached, the results will be statistically analysed. Parallels will be drawn between the responses obtained by the usual means and those captured in the questionnaires to be validated. It is expected that, in all cases, the degree of control and severity represented in the questionnaires to be validated will conform to the EPOS criteria and to the results of the questionnaires usually used. The results will be compared for each of the new questionnaires in general and separately by language. The ultimate goal is to validate what will become the diagnostic gold standard for chronic rhinosinusitis.

Trial sites (32)

FacilityCityRegionStatus
UCLA Santa Monica Medical Center Santa Monica California Recruiting
Northwestern University Feinberg School of Medicine Chicago Illinois Recruiting
Brigham Sinus Center at Brigham and Women's Hospital Boston Massachusetts Recruiting
Thomas Jefferson University Hospital Philadelphia Pennsylvania Recruiting
Eastern Virginia Medical School Virginia City Virginia Recruiting
UZ Gent Ghent Belgium Not Yet Recruiting
UZ Leuven Leuven Belgium Recruiting
St. Michael's Hospital Toronto Canada Recruiting
Univ of Copenhagen Copenhagen Denmark Recruiting
HNO-Klinik, Universitätsklinikum Düsseldorf Düsseldorf Germany Not Yet Recruiting
Univ Munich Munich Germany Not Yet Recruiting
University General Hospital of Heraklion Heraklion Greece Recruiting
U. Aristotle Thessaloniki Greece Recruiting
Univ Hospital Roma Roma Italy Recruiting
Univ Amsterdam Amsterdam Netherlands Not Yet Recruiting
Alrijne Zorggroep Leiden Netherlands Recruiting
University of Oradea Oradea Romania Recruiting
Ahmed Alkhadi Hospital Durban South Africa Recruiting
Hospital Clínico Universitario de Compostela A Coruña Spain Recruiting
Hospital Clinic Barcelona Barcelona Spain Recruiting
Hospital de la Santa Creu i Sant Pau Barcelona Spain Recruiting
Hospital de La Línea de La Concepción Cadiz Spain Recruiting
Hospital Universitario Jerez de La Frontera Cadiz Spain Recruiting
Hospital Universitario Puerta del Mar Cadiz Spain Recruiting
Hospital Universitario Puerto Real Cadiz Spain Recruiting
Hospital Universitario Fuenlabrada Madrid Spain Recruiting
Hospital Universitario Infanta Elena, Madrid y Hospital Universitario Fundación Jiménez Díaz Madrid Spain Recruiting
Hospital Universitario Ramón y Cajal Madrid Spain Recruiting
Hospital del Bierzo Ponferrada Spain Recruiting
Hospital Universitario Marqués de Valdecilla Santander Spain Recruiting
Hospital Universitario Virgen Macarena Seville Spain Recruiting
Hospital General Universitario de Valencia Valencia Spain Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06970977 on ClinicalTrials.gov ↗ ← All trials in Italy